Published in PLoS One on September 11, 2012
Can Fasting Decrease the Side Effects of Chemotherapy? | NCT04027478
Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression. Exp Gerontol (2013) 1.57
Dysregulated metabolism contributes to oncogenesis. Semin Cancer Biol (2015) 1.03
The ketogenic diet for the treatment of malignant glioma. J Lipid Res (2014) 1.03
Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agents. Cell Cycle (2013) 1.00
Autophagy in blood cancers: biological role and therapeutic implications. Haematologica (2013) 0.99
Fasting, Circadian Rhythms, and Time-Restricted Feeding in Healthy Lifespan. Cell Metab (2016) 0.95
Energetic interventions for healthspan and resiliency with aging. Exp Gerontol (2016) 0.92
Calories, carbohydrates, and cancer therapy with radiation: exploiting the five R's through dietary manipulation. Cancer Metastasis Rev (2014) 0.92
The links between insulin resistance, diabetes, and cancer. Curr Diab Rep (2013) 0.92
Fasting induces anti-Warburg effect that increases respiration but reduces ATP-synthesis to promote apoptosis in colon cancer models. Oncotarget (2015) 0.89
Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition. Oncotarget (2015) 0.88
Protective properties of radio-chemoresistant glioblastoma stem cell clones are associated with metabolic adaptation to reduced glucose dependence. PLoS One (2013) 0.87
Starvation promotes REV1 SUMOylation and p53-dependent sensitization of melanoma and breast cancer cells. Cancer Res (2015) 0.86
Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. J Neurooncol (2015) 0.86
To diet or not to diet - that is still the question. Neuro Oncol (2016) 0.85
Fasting protects mice from lethal DNA damage by promoting small intestinal epithelial stem cell survival. Proc Natl Acad Sci U S A (2015) 0.83
The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study. BMC Cancer (2015) 0.81
Restricting carbohydrates to fight head and neck cancer-is this realistic? Cancer Biol Med (2014) 0.80
Antitumor activity of a polypyridyl chelating ligand: in vitro and in vivo inhibition of glioma. ASN Neuro (2015) 0.79
Tumor Metabolism, the Ketogenic Diet and β-Hydroxybutyrate: Novel Approaches to Adjuvant Brain Tumor Therapy. Front Mol Neurosci (2016) 0.79
Transient fasting enhances replication of oncolytic herpes simplex virus in glioblastoma. Am J Cancer Res (2016) 0.76
γ-H2AX as a marker for dose deposition in the brain of wistar rats after synchrotron microbeam radiation. PLoS One (2015) 0.75
Aging, nutrient signaling, hematopoietic senescence, and cancer. Crit Rev Oncog (2013) 0.75
Differential effects of patient-related factors on the outcome of radiation therapy for rectal cancer. J Radiat Oncol (2016) 0.75
Ramadan Fasting and Patients with Cancer: State-of-the-Art and Future Prospects. Front Oncol (2016) 0.75
Fasting plus tyrosine kinase inhibitors in cancer. Aging (Albany NY) (2015) 0.75
Diallyl disulfide enhances carbon ion beams-induced apoptotic cell death in cervical cancer cells through regulating Tap73 /ΔNp73. Cell Cycle (2015) 0.75
Calorie restriction in rodents: Caveats to consider. Ageing Res Rev (2017) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65
Malignant gliomas in adults. N Engl J Med (2008) 20.54
On respiratory impairment in cancer cells. Science (1956) 14.07
Extending healthy life span--from yeast to humans. Science (2010) 12.12
Fasting serum glucose level and cancer risk in Korean men and women. JAMA (2005) 6.69
Understanding the odd science of aging. Cell (2005) 6.50
Epidemiology and etiology of gliomas. Acta Neuropathol (2005) 6.14
Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst (2000) 5.77
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol (2002) 4.50
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol (2008) 4.32
Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol (2011) 3.41
Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci U S A (2008) 3.30
Temozolomide and treatment of malignant glioma. Clin Cancer Res (2000) 2.95
The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res (2007) 2.82
Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res (1987) 2.72
Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev (1997) 2.62
Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med (2012) 2.58
Mammalian abasic site base excision repair. Identification of the reaction sequence and rate-determining steps. J Biol Chem (1998) 2.49
Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget (2011) 2.28
Poor-prognosis high-grade gliomas: evolving an evidence-based standard of care. Lancet Oncol (2002) 2.23
Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys (1996) 2.15
Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia (2006) 1.87
Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med (2009) 1.83
High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res (2000) 1.80
Fasting and cancer treatment in humans: A case series report. Aging (Albany NY) (2009) 1.71
Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res (2010) 1.69
Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients. Oncogene (2011) 1.65
Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br J Cancer (2003) 1.61
Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol (2009) 1.53
The flexible genome. Nat Rev Genet (2001) 1.52
Advances in the genetics of glioblastoma: are we reaching critical mass? Nat Rev Neurol (2009) 1.48
Short-term dietary restriction and fasting precondition against ischemia reperfusion injury in mice. Aging Cell (2009) 1.47
The nature of gliomas as revealed by animal experimentation. Am J Pathol (1955) 1.42
Malignant gliomas in 2005: where to GO from here? JAMA (2005) 1.36
Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res (2003) 1.32
Baseline levels of glucose metabolites, glutamate and glycerol in malignant glioma assessed by stereotactic microdialysis. J Neurooncol (2003) 1.31
Maneuvering in the complex path from genotype to phenotype. Science (2002) 1.11
Gliomas are driven by glycolysis: putative roles of hexokinase, oxidative phosphorylation and mitochondrial ultrastructure. Anticancer Res (1997) 1.10
Roles for insulin-like growth factor-1 in mediating the anti-carcinogenic effects of caloric restriction. J Nutr Health Aging (1999) 1.07
Temozolomide: a milestone in neuro-oncology and beyond? Expert Rev Anticancer Ther (2006) 1.02
Cancer cachexia: influence of systemic ketosis on substrate levels and nitrogen metabolism. Am J Clin Nutr (1988) 0.98
Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy. Bone Marrow Transplant (1998) 0.92
Effects of 5-bromo-2-deoxyuridine and 2-deoxy-D-glucose on radiation-induced micronuclei in mouse bone marrow. Int J Radiat Biol (1990) 0.83
Chemotherapy for malignant gliomas. Semin Radiat Oncol (2009) 0.81
A review of the use of chemoprotectants in cancer chemotherapy. Drug Saf (1994) 0.77
Extending healthy life span--from yeast to humans. Science (2010) 12.12
Sir2 blocks extreme life-span extension. Cell (2005) 4.25
The chronological life span of Saccharomyces cerevisiae. Aging Cell (2003) 3.98
Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med (2011) 3.84
SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons. Cell Metab (2008) 3.35
Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci U S A (2008) 3.30
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest (2012) 3.14
Hyperspectral and multispectral bioluminescence optical tomography for small animal imaging. Phys Med Biol (2005) 3.11
Life span extension by calorie restriction depends on Rim15 and transcription factors downstream of Ras/PKA, Tor, and Sch9. PLoS Genet (2007) 3.07
Superoxide is a mediator of an altruistic aging program in Saccharomyces cerevisiae. J Cell Biol (2004) 2.88
The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res (2007) 2.82
SOD2 functions downstream of Sch9 to extend longevity in yeast. Genetics (2003) 2.81
Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood (2009) 2.61
Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med (2012) 2.58
Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity (2006) 2.56
In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res (2004) 2.46
RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res (2012) 2.41
Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. J Nucl Med (2004) 2.26
Tor1/Sch9-regulated carbon source substitution is as effective as calorie restriction in life span extension. PLoS Genet (2009) 2.18
MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol (2004) 2.18
MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem (2004) 2.15
Proteome analysis of laser microdissected glomeruli from formalin-fixed paraffin-embedded kidneys of autopsies of diabetic patients: nephronectin is associated with the development of diabetic glomerulosclerosis. Nephrol Dial Transplant (2011) 2.12
microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med (2004) 2.05
18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol (2004) 1.99
CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood (2009) 1.94
Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood (2007) 1.83
Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide. Mol Imaging (2004) 1.76
Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer (2013) 1.73
Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol (2004) 1.72
The chronological life span of Saccharomyces cerevisiae. Methods Mol Biol (2007) 1.72
Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. J Nucl Med (2002) 1.72
Fasting and cancer treatment in humans: A case series report. Aging (Albany NY) (2009) 1.71
SIRT1 is essential for normal cognitive function and synaptic plasticity. J Neurosci (2010) 1.71
Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res (2010) 1.69
Tetrazine-trans-cyclooctene ligation for the rapid construction of 18F labeled probes. Chem Commun (Camb) (2010) 1.69
Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo. Cancer Biol Ther (2005) 1.68
Existence of no hepatocarcinogenic effect levels of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline with or without coadministration with ethanol. Toxicol Pathol (2006) 1.66
Peroxynitrite mediates neurotoxicity of amyloid beta-peptide1-42- and lipopolysaccharide-activated microglia. J Neurosci (2002) 1.66
Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines. Cancer Biol Ther (2004) 1.65
Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J Urol (2013) 1.64
Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. J Nucl Med (2002) 1.60
MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging (2004) 1.60
Genome-wide screen in Saccharomyces cerevisiae identifies vacuolar protein sorting, autophagy, biosynthetic, and tRNA methylation genes involved in life span regulation. PLoS Genet (2010) 1.59
Stress chaperone GRP78/BiP confers chemoresistance to tumor-associated endothelial cells. Mol Cancer Res (2008) 1.58
Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression. Exp Gerontol (2013) 1.57
Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia (2005) 1.54
Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology (2002) 1.53
Smad3 deficiency promotes tumorigenesis in the distal colon of ApcMin/+ mice. Cancer Res (2006) 1.52
NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med (2012) 1.52
Self-assembled multivalent DNA nanostructures for noninvasive intracellular delivery of immunostimulatory CpG oligonucleotides. ACS Nano (2011) 1.52
Factors influencing the removal of fluoride from aqueous solution by calcined Mg-Al-CO3 layered double hydroxides. J Hazard Mater (2005) 1.49
TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol (2008) 1.43
Compared study of Asian reduction malarplasty: wedge-section osteotomy versus conventional procedures. J Craniofac Surg (2009) 1.41
Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. Mol Cancer Ther (2007) 1.41
Primary intraosseous meningioma. Neurosurg Focus (2007) 1.39
Tetrazine-trans-cyclooctene ligation for the rapid construction of integrin αvβ₃ targeted PET tracer based on a cyclic RGD peptide. Bioorg Med Chem Lett (2011) 1.36
Platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cytotoxicity. Cancer Sci (2009) 1.33
Superoxide inhibits 4Fe-4S cluster enzymes involved in amino acid biosynthesis. Cross-compartment protection by CuZn-superoxide dismutase. J Biol Chem (2004) 1.33
The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. Urol Oncol (2012) 1.33
Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res (2007) 1.33
NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human. J Clin Invest (2011) 1.30
HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res (2007) 1.30
Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol Sci (2009) 1.29
Longevity mutation in SCH9 prevents recombination errors and premature genomic instability in a Werner/Bloom model system. J Cell Biol (2008) 1.26
Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol Ther (2005) 1.25
The sodium bicarbonate cotransporter (NBCe1) is essential for normal development of mouse dentition. J Biol Chem (2010) 1.25
Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. Oncologist (2009) 1.25
DNA damage repair in bladder urothelium after the Chernobyl accident in Ukraine. J Urol (2002) 1.25
Radiopharmaceutical chemistry for positron emission tomography. Adv Drug Deliv Rev (2010) 1.24
Oncogene homologue Sch9 promotes age-dependent mutations by a superoxide and Rev1/Polzeta-dependent mechanism. J Cell Biol (2009) 1.23
Micelle density regulated by a reversible switch of protein secondary structure. J Am Chem Soc (2006) 1.21
MicroRNA-340 suppresses osteosarcoma tumor growth and metastasis by directly targeting ROCK1. Biochem Biophys Res Commun (2013) 1.20
Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med (2012) 1.19
Development and evaluation of 18F-TTCO-Cys40-Exendin-4: a PET probe for imaging transplanted islets. J Nucl Med (2013) 1.19
Formation of and coalescence from the inclusion complex of a biodegradable block copolymer and alpha-cyclodextrin. 2: A novel way to regulate the biodegradation behavior of biodegradable block copolymers. Biomacromolecules (2002) 1.19
A cocrystal strategy to tune the luminescent properties of stilbene-type organic solid-state materials. Angew Chem Int Ed Engl (2011) 1.18
Involvement of ubiquitination and sumoylation in bladder lesions induced by persistent long-term low dose ionizing radiation in humans. J Urol (2006) 1.18
Fasting and differential chemotherapy protection in patients. Cell Cycle (2010) 1.18
T-POP array identifies EcnR and PefI-SrgD as novel regulators of flagellar gene expression. J Bacteriol (2008) 1.18
The C-terminal region of activation-induced cytidine deaminase is responsible for a recombination function other than DNA cleavage in class switch recombination. Proc Natl Acad Sci U S A (2009) 1.18
Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiol (2002) 1.16